ConductScience.org, home

Paper37535237

The anti-inflammatory and immunological properties of SGLT-2 inhibitors.

Bendotti G and 5 others. J Endocrinol Invest, 2023. Cited by 41 papers, by iCite.

Cite this record

ConductScience Library. The anti-inflammatory and immunological properties of SGLT-2 inhibitors. Papers, record 37535237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37535237

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
PubMed
Journal
J Endocrinol Invest
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
4.67
iCite
Revised in PubMed
2026-10-31
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bendotti GG
2Montefusco LL
3Pastore II
4Lazzaroni EE
5Lunati MEM E
6Fiorina PPhttps://orcid.org/0000-0002-1093-7724

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Diabetes Mellitus, Type 2Major topic
Humans
Hypoglycemic Agents
Anti-Inflammatory Agents
Glucose

References81

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136134918Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.Diabetes Care2022https://conductscience.org/library/papers/36134918PubMed
233728820Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease.FEBS Open Bio2021https://conductscience.org/library/papers/33728820PubMed
333160017
The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.
Cell Signal2021https://conductscience.org/library/papers/33160017PubMed
421838680The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach.Curr Diabetes Rev2011https://conductscience.org/library/papers/21838680PubMed
531011203A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.Nat Med2019https://conductscience.org/library/papers/31011203PubMed
631477497SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.Cell Metab2019https://conductscience.org/library/papers/31477497PubMed
73906359Protein glycosylation and the pathogenesis of atherosclerosis.Metabolism1985https://conductscience.org/library/papers/3906359PubMed
829573529Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.Diabetes Obes Metab2018https://conductscience.org/library/papers/29573529PubMed
98596407Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients.Lancet1996https://conductscience.org/library/papers/8596407PubMed
1035620570Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes.J Diabetes Res2022https://conductscience.org/library/papers/35620570PubMed
1120447870Immunological and regenerative properties of cord blood stem cells.Clin Immunol2010https://conductscience.org/library/papers/20447870PubMed
1216290958Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study.Am Heart J2005https://conductscience.org/library/papers/16290958PubMed
1331001673Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.Diabetologia2019https://conductscience.org/library/papers/31001673PubMed
1429923295
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
Diabetes Obes Metab2018https://conductscience.org/library/papers/29923295PubMed
1535712355Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes.Front Mol Biosci2022https://conductscience.org/library/papers/35712355PubMed
1616168295
Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study.
J Am Coll Cardiol2005https://conductscience.org/library/papers/16168295PubMed
1728104929The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice.Mediators Inflamm2016https://conductscience.org/library/papers/28104929PubMed
1833771372Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy.Hum Immunol2021https://conductscience.org/library/papers/33771372PubMed
1935126822Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice.Oxid Med Cell Longev2022https://conductscience.org/library/papers/35126822PubMed
2032726607SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.Cell Metab2020https://conductscience.org/library/papers/32726607PubMed

See all 81 referencesDownload CSV of references

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
42959627Decoding inflammation to target hybrid diabetes phenotypes.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42959627PubMed
42681829Initiation of SGLT2 Inhibitors Versus DPP-4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims-Based Active-Comparator New-User Study.Diabetes Obes Metab2026https://conductscience.org/library/papers/42681829PubMed
42591999Mitochondrial-inflammatory coupling in HFpEF: an emerging mechanistic framework for understanding the cardioprotective effects of SGLT2 inhibitors.Front Cardiovasc Med2026https://conductscience.org/library/papers/42591999PubMed
42233563SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease.JACC Asia2026https://conductscience.org/library/papers/42233563PubMed
41771397Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients With Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study.J Card Fail2026https://conductscience.org/library/papers/41771397PubMed
41752654Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin.Medicina (Kaunas)2026https://conductscience.org/library/papers/41752654PubMed
41619161Henagliflozin enhances frontal neural activation and cognitive function versus gliclazide in type 2 diabetes patients with mild cognitive impairment: A 16-week randomized controlled trial.J Endocrinol Invest2026https://conductscience.org/library/papers/41619161PubMed
41505051Amputation and gangrene associated with SGLT2 inhibitors: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.J Endocrinol Invest2026https://conductscience.org/library/papers/41505051PubMed
41489806Sodium-glucose cotransporter-2 inhibitors and sepsis: a story with two tails or with one tail?Inflammopharmacology2026https://conductscience.org/library/papers/41489806PubMed
41469686Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation.BMC Med2025https://conductscience.org/library/papers/41469686PubMed
41126323The association between glycated hemoglobin and intraocular inflammatory factors in patients with proliferative diabetic retinopathy.Int J Retina Vitreous2025https://conductscience.org/library/papers/41126323PubMed
41093607Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study.BMJ2025https://conductscience.org/library/papers/41093607PubMed
40978121Sodium-glucose co-transporter-2 inhibitors vs metformin in reducing osteoarthritis risk: a retrospective cohort study of health insurance claims and check-up data.JBMR Plus2025https://conductscience.org/library/papers/40978121PubMed
40696035Relationship between aggregate index of systemic inflammation and mortality from CCD and malignant neoplasms in diabetic patients.Sci Rep2025https://conductscience.org/library/papers/40696035PubMed
40665981Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety.Front Med (Lausanne)2025https://conductscience.org/library/papers/40665981PubMed
40620843Impact of Albuminuria and Renal Dysfunction on the Anemia-Improving Effect of SGLT2 Inhibitors in Patients With Type 2 Diabetes: A Real-World Observational Study.J Diabetes Res2025https://conductscience.org/library/papers/40620843PubMed
40420176Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review.Cardiovasc Diabetol2025https://conductscience.org/library/papers/40420176PubMed
40193211Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies.J Am Soc Nephrol2025https://conductscience.org/library/papers/40193211PubMed
40127201Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study.Rheumatology (Oxford)2025https://conductscience.org/library/papers/40127201PubMed
40123308Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes.J Diabetes Investig2025https://conductscience.org/library/papers/40123308PubMed

See all 30 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37535237

GET https://conductscience.org/api/papers/v1/37535237/references?page=2